Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

Annals of Oncology ◽

10.1093/annonc/mdr399 ◽

2012 ◽

Vol 23 (5) ◽

pp. 1234-1240 ◽

Author(s):

M.D. Michaelson ◽

J. Bellmunt ◽

G.R. Hudes ◽

S. Goel ◽

R.J. Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Multicenter Phase

Download Full-text

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-012-1896-9 ◽

2012 ◽

Vol 70 (1) ◽

pp. 161-168 ◽

Author(s):

N. Kentepozidis ◽

A. Soultati ◽

S. Giassas ◽

N. Vardakis ◽

A. Kalykaki ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Research Group ◽

Phase Ii Study ◽

Salvage Treatment ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Oncology Research ◽

Multicenter Phase

Download Full-text

A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2011.12.023 ◽

2012 ◽

Vol 48 (5) ◽

pp. 678-686 ◽

Author(s):

S. Nilsson ◽

P. Strang ◽

A.K. Aksnes ◽

L. Franzèn ◽

P. Olivier ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Dose Response ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Multicenter Phase ◽

Painful Bone Metastases

Download Full-text

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Download Full-text

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

Download Full-text

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)

Annals of Oncology ◽

10.1093/annonc/mdy284.068 ◽

2018 ◽

Vol 29 ◽

pp. viii301

Author(s):

J.S. de Bono ◽

C. Higano ◽

F. Saad ◽

K. Miller ◽

M. Casey ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Response Rate ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Download Full-text

Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1722 ◽

2009 ◽

Vol 15 (22) ◽

pp. 7099-7105 ◽

Author(s):

Mary-Ellen Taplin ◽

Meredith M. Regan ◽

Yoo-Joung Ko ◽

Glenn J. Bubley ◽

Stephen E. Duggan ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Synthesis Inhibition ◽

Androgen Synthesis ◽

Castration Resistant

Download Full-text

900 OPEN-LABEL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF PERSONALIZED PEPTIDE VACCINATION (PPV) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER(CRPC)

The Journal of Urology ◽

10.1016/j.juro.2011.02.2609 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Masanori Noguchi ◽

Fukuko Moriya ◽

Shigetaka Suekane ◽

Kei Matsuoka ◽

Gaku Arai ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Castration Resistant Prostate Cancer ◽

Peptide Vaccination ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).

10.1158/1535-7163.targ-11-a221 ◽

2011 ◽

Author(s):

Bernhard J. Eigl ◽

Scott North ◽

Nevin Murray ◽

Daniel YC Heng ◽

Eric Winquist ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

10.1158/1538-7445.am2019-ct161 ◽

2019 ◽

Author(s):

David J. Einstein ◽

Atish Choudhury ◽

Philip Saylor ◽

Lillian Werner ◽

Mark Erlander ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text